10-(2-oxo-2-Phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: Synthesis, antiproliferative activity, and inhibition of tubulin polymerization

Journal of Medicinal Chemistry

Volumn 52, Issue 5, 2009, Pages 1284-1294

  Prinz, Helge ^a   Schmidt, Peter ^b   Böhm, Konrad J ^c   Baasner, Silke ^b   Müller, Klaus ^a   Unger, Eberhard ^c   Gerlach, Matthias ^b   Günther, Eckhard G ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c Æterna Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

10 (1 HYDROXY 2 (3,4,5 TRIMETHOXYPHENYL) 2 OXOETHYL) 10H ANTHRACEN 9 ONE; 10 (1 HYDROXY 2 (4 METHOXYPHENYL) 2 OXOETHYL) 10H ANTHRACEN 9 ONE; 10 (1 HYDROXY 2 OXO 2 PHENYLETHYL) 10H ANTHRACEN 9 ONE; 10 (1 HYDROXY 2,2 DIMETHOXY ETHYL) 10H ANTHRACEN 9 ONE; 10 (2 OXO 2 PHENYLTHYLIDENE) 10 H ANTHRACEN 9 ONE; 10 [(2 OXO 2 THIOPHEN 2 YL ETHYLIDENE)] 10H ANTHRACEN 9 ONE; 10 [2 (2 HYDROXY 3,4 DIMETHOXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (2,4 DIMETHOXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (3 METHOXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (3,4 DIHYDROXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (3,4 DIMETHOXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (4 HYDROXY PHENYL) 2 OXO ETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (4 METHOXYPHENYL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 (4 METHOXYTHIOPHEN 2 YL) 2 OXOETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 OXO 2 (2,3,4 TRIMETHOXYPHENYL)ETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 OXO 2 (3,4,5 TRIMETHOXYPHENYL)ETHYLIDENE] 10H ANTHRACEN 9 ONE; 10 [2 OXO 2 P TOLYL ETHYLIDENE] 10H ANTHRACEN 9 ONE; 2 (ANTHRACEN 9 YLOXY) 1 (4 METHOXYPHENYL) ETHANONE; 2 [(10 HYDROXY 10H ANTHRACEN 9 YLIDENE)] 1 (4 METHOXYPHENYL)ETHANONE; [(10 OXO(10H)ANTHRACENCENE 9 YLIDENE)]ACETIC ACID 2 METHOXYPHENYL ESTER; [(10 OXO(10H)ANTHRACENE 9 YLIDENE)]ACETIC ACID 2,6 DIMETHOXYPHENYL ESTER; ANTHRACENE DERIVATIVE; GROWTH INHIBITOR; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN KB; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; FLOW CYTOMETRY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN INTERACTION; RAT; TUMOR CELL;

ANTHRACENES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 64349107236     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801338r     Document Type: Article

References (46)

1. Honore, S.; Pasquier, E.; Braguer, D. Understanding microtubule dynamics for improved cancer therapy. Cell. Mol life sci. 2005, 62, 3039-3056.
2. Pellegrini, F.; Budman, D. R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005, 23, 264-273.
3. Hearn, B. R.; Shaw, S. J.; Myles, D. C. Microtubule targeting agents. Compr. Med. Chem. II 2007, 7, 81-110.
4. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2002, 2, 1-17.
5. Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin. Ther. Patents 2002, 12, 1663-1702.
6. Mahindroo, N.; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents for the treatment of cancer-a medicinal chemistry update. Expert Opin. Ther. Patents 2006, 16, 647-691.
7. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia- Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45, 209-211.
8. Goodin, S.; Kane, M. P.; Rubin, E. H. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 2004, 22, 2015-2025.
9. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer. Res. 1997, 57, 3208-3213.
10. Sirisoma, N.; Kasibhatla, S.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M. B.; Baichwal, V.; Mather, G. G.; Jessing, K.; Hussain, R.; Hoang, K.; Pleiman, C. M.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 2-chloro-A-(4-methoxyphenyl)-A-meth- ylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer ofapoptosis withhigh in vivo activity. J. Med. Chem. 2008, 51, 4771-4779.
11. Baasner, S.; Emig, P.; Gerlach, M.; Müller, G.; Paulini, K.; Schmidt, P.; Burger, A. M.; Fiebig, H.-H.; Günther, E. G. D-82318-A novel, synthetic, low molecular weight tubulin inhibitor with potent in vivo antitumor activity. EORTC-NCI-AACR Meeting, Frankfurt, Germany, 2002, Poster 112.
12. Meng, F.; Cai, X.; Duan, J.; Matteucci, M. G.; Hart, C. P. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother. Pharmacol. 2008, 61, 953-963.
13. Zhang, L. H.; Wu, L.; Raymon, H. K.; Chen, R. S.; Corral, L.; Shirley, M. A.; Narla, R. K.; Gamez, J.; Muller, G. W.; Stirling, D. I.; Bartlett, J. B.; Schafer, P. H.; Payvandi, F. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer. Res. 2006, 66, 951-959.
14. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res. 2003, 5, 309-25.
15. Prinz, H.; Ishii, Y.; Hirano, T.; Stoiber, T.; Camacho Gomez, J. A.; Schmidt, P.; Dussmann, H.; Burger, A. M.; Prehn, J. H.; Gunther, E. G.; Unger, E.; Umezawa, K. Novel benzylidene-9(10/f)-anthra- cenones as highly active antimicrotubule agents. Synthesis, antipro- liferative activity, and inhibition of tubulin polymerization. J. Med. Chem. 2003, 46, 3382-3394.
16. Zuse, A.; Schmidt, P.; Baasner, S.; Bohm, K. J.; Müller, K.; Gerlach, M.; Günther, E. G.; Unger, E.; Prinz, H. 9-Benzylidene-naphtho[2, 3- b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antipro- liferative activity, and inhibition of tubulin polymerization. J. Med. Chem. 2006, 49, 7816-7825.
17. Zuse, A.; Schmidt, P.; Baasner, S.; Bohm, K. J.; Muller, K.; Gerlach, M.; Günther, E. G.; Unger, E.; Prinz, H. Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9//)-one and 9(10/f)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization. J. Med. Chem. 2007, 50, 6059-6066.
18. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des. 2005, 11, 1679-1693.
19. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Mahindroo, N.; Kuo, F. M.; Hsieh, H. P. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J. Med. Chem. 2004, 47, 2897-2905.
20. Afsah, E. M.; Etman, H. A.; Hamama, W. S.; Sayed-Ahmed, A. F. A study on the reaction of 1,3-indandione with Schiff bases: synthesis of new 1,3-indandiones with expected psychopharmacological and anticoagulant activit. Boll. Chim. Farm. 1998, 137, 244-248.
21. El-Shafie, S. M. M. Synthesis of 10-arylidene-9-anthrones and related compounds. Indian J. Chem. 1978, 16B, 828-830.
22. Bergmann, E. D.; Rabinovitz, M.; Glily, S. A ring enlargement in the 9,10-dihydroanthracene series. Tetrahedron Suppl. 1966, 8, 141-148.
23. Weitz, E. Uber einige Anthronabkömmlinge. Liebiss Ann. Chem. 1919, 418, 29-35.
24. Rappoport, Z.; Apeloig, Y.; Greenblatt, J. Vinylic cations from solvolysis. 29. Solvolysis of 9-(α-bromoarylidene)anthrones as a probe to the reactivity- selectivity relationship in solvolysis reactions. J. Am. Chem. Soc. 1980, 102, 3837-3848.
25. Müller, K.; Gürster, D.; Piwek, S.; Wiegrebe, W. Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10/f)-anthracenones as inhibitors of 5-lipoxygenase. J. Med. Chem. 1993, 36, 4099-4107.
26. Baba, H.; Takemura, T. Spectrophotometric investigations of the tautomeric reaction between anthrone and anthranol. I. The keto-enol equilibrium. Tetrahedron 1968, 24, 4779-4791.
27. Martin, R. Études sur la reaction de fries. XIV. Mécanismes engendrés dans les reactions acido-catalysees. IV. Preparation des acyl-5 gaiacols. Bull. Soc. Chim. Fr. 1977, 901-905.
28. Lozzio, C. B.; Lozzio, B. B. Human chronic myelogenous leukemia cell-line with positive philadelphia chromosome. Blood1975, 45, 321-334.
29. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Evaluation of a soluble tetrazolium/formazane assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988, 48, 4827-4833.
30. Kip1 in modulating chemosensitivity and their possible application in drug discovery studies. Mol. Pharmacol. 2001, 60, 900-906.
31. Dumontet, C.; Jaffrezou, J. P.; Tsuchiya, E.; Duran, G. E.; Chen, G.; Derry, W. B.; Wilson, L.; Jordan, M. A.; Sikic, B. I. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull. Cancer 2004, 91, 81-112.
32. Dumontet, C.; Sikic, B. I. Mechanism of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999, 3, 1061-1070.
33. Fardel, O.; Lecureur, V.; Guillouzo, A. The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27, 1283-1291.
34. Cole, S. P.; Deeley, R. G. Multidrug resistance mediated by the ATP- binding cassette transporter protein MRP. BioEssays 1998, 20, 931-940.
35. Kavallaris, M.; Annereau, J. P.; Barret, J. M. Potential mechanisms of resistance to microtubule inhibitors. Semin. Oncol. 2008, 35, 22-27.
36. Verrills, N. M.; Kavallaris, M. Improving the targeting of tubulin- binding agents: lessons from drug resistance studies. Curr. Pharm. Des. 2005, 11, 1719-1733.
37. Tahir, S. K.; Kovar, P.; Rosenberg, S.; Ng, S.-C. A rapid colchicine competition-binding scintillation proximity assay using biotin-labeled colchicine. Biotechniques 2000, 29, 156-160.
38. Bai, R.; Roach, M. C.; Jayaram, S. K.; Barkoczy, J.; Pettit, G. R.; Luduena, R. F.; Hamel, E. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem. Pharmacol. 1993, 45, 1503-1515.
39. Bai, R. L.; Pettit, G. R.; Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 1990, 265, 17141-17149.
40. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
41. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem. 2005, 48, 6107-6116.
42. Zefirova, O. N.; Diikov, A. G.; Zyk, N. V.; Zefirov, N. S. Ligands of the colchicine site of tubulin: a common pharmacophore and new structural classes. Russ. Chem. Bull. Int. Ed. 2007, 56, 680-688.
43. Schmidt, M.; Lu, Y.; Liu, B.; Fang, M.; Mendelsohn, J.; Fan, Z. Differential modulation of paclitaxel-mediated apoptosis by p21waf1 and p27kip1. Oncogene 2000, 19, 2423-2429.
44. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficiacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 2001, 61, 392-399.
45. Shelanski, M. L.; Gaskin, F.; Cantor, C. R. Microtubule assembly in the absence of added nucleotides. Proc. Nat. Acad. Sci. U.S.A. 1973, 70, 765-768.
46. Vater, W.; Böhm, K. J.; Unger, E. A simple method to obtain brain microtubule protein poor in microtubule-associated proteins. Acta Histochem. Suppl. 1986, 33, 123-129.